- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Proactive CRS Management: The Role of Tocilizumab and Beyond
Amrita Krishnan, MD, discusses how data from ASH 2024 highlight the critical role of intravenous immunoglobulin (IVIG) treatment in preventing infections in patients receiving teclistamab, shares her approach to incorporating IVIG into clinical practice, and outlines additional strategies for reducing infection risk and managing cytokine release syndrome (CRS) in patients on bispecific antibody therapies for multiple myeloma.
EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management
EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond
EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
EP: 5.Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
EP: 6.Streamlining Transitions Between Academic and Community Centers
EP: 7.Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery
Video content above is prompted by the following:
- Data from ASH 2024 suggest intravenous immunoglobulin (IVIG) can play a critical role in preventing infections in patients receiving teclistamab. How do you incorporate IVIG into your clinical practice, and what considerations guide its use?
- Beyond IVIG, what additional strategies or prophylactic measures have you incorporated into your practice to reduce infection risk in patients on bispecific antibody therapies in multiple myeloma?
- Cytokine release syndrome (CRS) remains a common concern with bispecific antibodies. What strategies do you find most effective for managing CRS?
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
